The role of structural information in the discovery of direct thrombin and factor Xa inhibitors

Trends in Pharmacological Sciences

Volumn 33, Issue 5, 2012, Pages 279-288

  Nar, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; APIXABAN; ARGATROBAN; BENZAMIDINE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; MELAGATRAN; PARACETAMOL; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR; XIMELAGATRAN;

BINDING AFFINITY; BLOOD CLOTTING; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; THROMBOSIS;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION FACTOR INHIBITORS; DRUG DESIGN; FACTOR XA; HUMANS; PROTEIN CONFORMATION; PROTHROMBIN; THROMBIN;

EID: 84860536853     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.03.004     Document Type: Review

References (64)

1. D.S. Whitlon Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition Biochemistry 17 1978 1371 1377 (Pubitemid 8330368)
2. M.D. Freedman Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects J. Clin. Pharmacol. 32 1992 196 209
3. C.D. Mathers, and D. Loncar Projections of global mortality and burden of disease from 2002 to 2030 PLoS Med. 3 2006 e442
4. R. Beaglehole, and R. Bonita Global public health: a scorecard Lancet 372 2008 1988 1996
5. D. Gustafsson A new oral anticoagulant: the 50-year challenge Nat. Rev. Drug Discov. 3 2004 649 659 (Pubitemid 39173506)
6. Y.K. Lee, and M.R. Player Developments in factor Xa inhibitors for the treatment of thromboembolic disorders Med. Res. Rev. 31 2011 202 283
7. D.J. Pinto Factor Xa inhibitors: next-generation antithrombotic agents J. Med. Chem. 53 2010 6243 6274
8. A. Straub Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? Angew. Chem. Int. Ed. Engl. 50 2011 4574 4590
9. R.J. Young The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry? Bioorg. Med. Chem. Lett. 21 2011 6228 6235
10. W. Bode, and P. Schwager The refined crystal structure of bovine beta-trypsin at 1.8 resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7. 0 J. Mol. Biol. 98 1975 693 717
11. S.T. Freer Chymotrypsinogen: 2.5-angstrom crystal structure, comparison with alpha-chymotrypsin, and implications for zymogen activation Biochemistry 9 1970 1997 2009
12. H. Brandstetter X-Ray structure of active site-inhibited clotting factor Xa, Implications for drug design and substrate recognition J. Biol. Chem. 271 1996 29988 29992 (Pubitemid 26389636)
13. W. Bode The refined 1.9 crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment EMBO J. 8 1989 3467 3475 (Pubitemid 19273577)
14. K. Padmanabhan Structure of human des(1-45) factor Xa at 2.2 resolution J. Mol. Biol. 232 1993 947 966 (Pubitemid 23256984)
15. W. Bode Geometry of binding of the benzamidine- and arginine-based inhibitors Nα-(2-naphthyl-sulphonyl-glycyl)-D, L-p-amidinophenylalanyl- piperidine (NAPAP) and (2R,4R)-4-methyl-1-[Nα-(3-methyl-1,2,3,4- tetrahydro-8-quinolinesulphonyl)-L-arginyl]-2-piperidine carboxylic acid (MQPA) to human alpha-thrombin. X-Ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin Eur. J. Biochem. 193 1990 175 182
16. T. Matsuzaki X-Ray analysis of a thrombin inhibitor-trypsin complex J. Biochem. 105 1989 949 952 (Pubitemid 19147426)
17. D.W. Banner, and P. Hadvary Crystallographic analysis at 3.0-Å resolution of the binding to human thrombin of four active site-directed inhibitors J. Biol. Chem. 266 1991 20085 20093 (Pubitemid 21908430)
18. H. Brandstetter Refined 2.3 X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics J. Mol. Biol. 226 1992 1085 1099
19. E. Skrzypczak-Jankun Structure of the hirugen and hirulog 1 complexes of alpha-thrombin J. Mol. Biol. 221 1991 1379 1393 (Pubitemid 121003459)
20. K. Kamata Structural basis for chemical inhibition of human blood coagulation factor Xa Proc. Natl. Acad. Sci. U.S.A. 95 1998 6630 6635 (Pubitemid 28278031)
21. H. Nar Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors Structure 9 2001 29 37 (Pubitemid 32064347)
22. M.T. Stubbs pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design Chembiochem 3 2002 246 249 (Pubitemid 36004503)
23. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]- 2-piperidinecarboxylic acid Biochemistry 23 1984 85 90 (Pubitemid 14181541)
24. J. Sturzebecher Cyclic amides of Nα-arylsulfonylaminoacylated 4-amidinophenylalanine - tight binding inhibitors of thrombin Thromb. Res. 29 1983 635 642 (Pubitemid 13080955)
25. D. Gustafsson Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes Thromb. Haemost. 79 1998 110 118 (Pubitemid 28037068)
26. D. Gustafsson The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects Thromb. Res. 101 2001 171 181 (Pubitemid 32176022)
27. D. Gustafsson, and M. Elg The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review Thromb. Res. 109 Suppl. 1 2003 S9 S15
28. D. Gustafsson Discovery of ximelagatran in an historical perspective Semin. Vasc. Med. 5 2005 227 234 (Pubitemid 41243657)
29. N.H. Hauel Structure-based design of novel potent nonpeptide thrombin inhibitors J. Med. Chem. 45 2002 1757 1766 (Pubitemid 34415371)
30. G.J. Hankey, and J.W. Eikelboom Dabigatran etexilate: a new oral thrombin inhibitor Circulation 123 2011 1436 1450
31. N. Haginoya Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine as S4 binding element J. Med. Chem. 47 2004 5167 5182 (Pubitemid 39314914)
32. Z. Lin, and M.E. Johnson Proposed cation-pi mediated binding by factor Xa: a novel enzymatic mechanism for molecular recognition FEBS Lett. 370 1995 1 5
33. M.T. Stubbs Crystal structures of factor Xa specific inhibitors in complex with trypsin: structural grounds for inhibition of factor Xa and selectivity against thrombin FEBS Lett. 375 1995 103 107
34. E. Perzborn The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor Nat. Rev. Drug Discov. 10 2011 61 75
35. S. Roehrig Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl} methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor J. Med. Chem. 48 2005 5900 5908 (Pubitemid 41324601)
36. D.J. Pinto Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1- yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa J. Med. Chem. 50 2007 5339 5356 (Pubitemid 350057846)
37. M. Nazare Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography J. Med. Chem. 48 2005 4511 4525 (Pubitemid 40993413)
38. C. Tapparelli Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile Trends Pharmacol. Sci. 14 1993 366 376 (Pubitemid 23308760)
39. W.C. Lumma Jr. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis J. Med. Chem. 41 1998 1011 1013 (Pubitemid 28207376)
40. T.J. Tucker Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position J. Med. Chem. 41 1998 3210 3219 (Pubitemid 28376526)
41. A. Wei Crystallization and preliminary X-ray diffraction data of the complex of recombinant tick anticoagulant peptide (rTAP) and bovine factor Xa Acta Crystallogr. D: Biol. Crystallogr. 55 1999 862 864
42. B.Y. Zhu, and R.M. Scarborough Factor Xa inhibitors: recent advances in anticoagulant agents Annu. Rep. Med. Chem. 35 2000 83 103
43. M. Adler Crystal structures of two potent nonamidine inhibitors bound to factor Xa Biochemistry 41 2002 15514 15523 (Pubitemid 36062457)
44. J.J. Masters Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity J. Med. Chem. 43 2000 2087 2092 (Pubitemid 30354533)
45. W.W. Mederski, and M. Germann A general synthesis of 1-aryl carbamoyl-2-alkyl-4-aryl substituted semicarbazides as nonbasic factor Xa inhibitors Bioorg. Med. Chem. Lett. 13 2003 3715 3718 (Pubitemid 37206493)
46. H. Matter Evidence for C-Cl/C-Br···π interactions as an important contribution to protein-ligand binding affinity Angew. Chem. Int. Ed. Engl. 48 2009 2911 2916
47. R. Abel Role of the active-site solvent in the thermodynamics of factor Xa ligand binding J. Am. Chem. Soc. 130 2008 2817 2831 (Pubitemid 351416242)
48. B. Baum More than a simple lipophilic contact: a detailed thermodynamic analysis of nonbasic residues in the S1 pocket of thrombin J. Mol. Biol. 390 2009 56 69
49. C. Bissantz A medicinal chemist's guide to molecular interactions J. Med. Chem. 53 2010 5061 5084
50. Y.N. Imai Cl-π interactions in protein-ligand complexes Protein Sci. 17 2008 1129 1137
51. H. Matter Design and quantitative structure-activity relationship of 3-amidinobenzyl-1H-indole-2-carboxamides as potent, nonchiral, and selective inhibitors of blood coagulation factor Xa J. Med. Chem. 45 2002 2749 2769 (Pubitemid 34632656)
52. S. Maignan Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket J. Med. Chem. 46 2003 685 690 (Pubitemid 36258860)
53. J.P. Gallivan, and D.A. Dougherty Cation-π interactions in structural biology Proc. Natl. Acad. Sci. U.S.A. 96 1999 9459 9464
54. L.M. Salonen Cation-π interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions Angew. Chem. Int. Ed. Engl. 48 2009 811 814
55. L.M. Salonen Molecular recognition at the active site of factor Xa: cation-π interactions, stacking on planar peptide surfaces, and replacement of structural water Chemistry 18 2012 213 222
56. K. Scharer Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of factor Xa bound to a quaternary ammonium ion ligand Angew. Chem. Int. Ed. Engl. 44 2005 4400 4404 (Pubitemid 41026381)
57. R.J. Young Structure and property based design of factor Xa inhibitors: biaryl pyrrolidin-2-ones incorporating basic heterocyclic motifs Bioorg. Med. Chem. Lett. 18 2008 28 33
58. F. Markwardt Coagulation inhibitors from blood-sucking animals. A new line of developing antithrombotic drugs Pharmazie 49 1994 313 316 (Pubitemid 24165414)
59. W.R. Gould Inhibitors of blood coagulation factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro J. Thromb. Haemost. 4 2006 834 841
60. A. Kranjc, and D. Kikelj Dual inhibitors of the blood coagulation enzymes Curr. Med. Chem. 11 2004 2535 2547 (Pubitemid 39255549)
61. E.U. Graefe-Mody Pharmacokinetics and pharmacodynamics of BIBT 986, a novel small molecule dual inhibitor of thrombin and factor Xa J. Thromb. Haemost. 4 2006 1502 1509
62. J.Z. Deng Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization Bioorg. Med. Chem. Lett. 15 2005 4411 4416 (Pubitemid 41253866)
63. R.J. Young Selective and dual action orally active inhibitors of thrombin and factor Xa Bioorg. Med. Chem. Lett. 17 2007 2927 2930 (Pubitemid 46636275)
64. N. Howard Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors J. Med. Chem. 49 2006 1346 1355 (Pubitemid 43271886)